Senti Biosciences Business Summary

Senti Biosciences, Inc. (SNTI) is a clinical-stage biotechnology company that generates revenue primarily through strategic research collaborations, licensing agreements, and government grants, such as those from the California Institute for Regenerative Medicine (CIRM). The company operates through a single business segment focused on its proprietary Gene Circuit platform, which utilizes synthetic biology to engineer next-generation cell and gene therapies with enhanced precision and control. Its primary product candidates, including SENTI-202 for acute myeloid leukemia and SENTI-301A for hepatocellular carcinoma, leverage allogeneic chimeric antigen receptor natural killer (CAR-NK) cells equipped with logic-gated circuits. Senti Biosciences competes directly with established oncology players and cell therapy developers such as Kite Pharma (Gilead), Jazz Pharmaceuticals, Pyxis Oncology, and Caribou Biosciences, positioning itself as a specialized pioneer in "programmable" biology that offers superior safety and targeting through complex logic gating (e.g., "AND" and "NOT" gates) compared to traditional cell therapy approaches. The company was founded by a distinguished team of synthetic biology experts, led by Co-Founder and CEO Timothy Lu, M.D., Ph.D., a former tenured MIT faculty member with a pedigree in electrical engineering and biological engineering. The leadership team includes Chief Technology Officer and Co-Founder Philip Lee, Ph.D., Chief Financial Officer Jay Cross, who brings extensive healthcare investment banking experience, and Head of R&D and Chief Medical Officer Kanya Rajangam, M.D., Ph.D., who previously led clinical development at Nkarta and Atara Biotherapeutics. Scientific co-founders include MIT Professor James J. Collins, a MacArthur Fellow and pioneer in synthetic biology, and Wilson Wong, Ph.D. Senti is backed by a notable roster of investors and board members, including New Enterprise Associates (NEA), 8VC, Leaps by Bayer, and Celadon Partners, with recent board appointments such as Bryan Baum of K5 Global further strengthening its strategic oversight.